Animal models for autoimmune bullous dermatoses

Experimental Dermatology

Volumn 19, Issue 1, 2010, Pages 2-11

  Bieber, Katja ^a   Sun, Shijie ^a   Ishii, Norito ^a   Kasperkiewicz, Michael ^a   Schmidt, Enno ^a   Hirose, Misa ^a   Westermann, Jürgen ^a   Yu, Xinhua ^b   Zillikens, Detlef ^a   Ludwig, Ralf J ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b RESEARCH CENTER BORSTEL   (Germany)

Author keywords

Autoimmunity; Blistering; Epidermolysis bullosa acquisita; Pemphigoid; Pemphigus; Skin

Indexed keywords

AUTOANTIBODY; BULLOUS PEMPHIGOID ANTIGEN 1; CD11B ANTIGEN; COLLAGEN TYPE 7; COMPLEMENT COMPONENT C3; FREUND ADJUVANT; GELATINASE B; GLUTEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; LAMININ; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1;

ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN BINDING; ANTIGEN EXPRESSION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BLISTER; BULLOUS SKIN DISEASE; COMPLEMENT ACTIVATION; EPIDERMOLYSIS BULLOSA ACQUISITA; HISTOPATHOLOGY; LYMPHOCYTE TRANSFER; MAST CELL; MUCOUS MEMBRANE PEMPHIGOID; NONHUMAN; PASSIVE IMMUNIZATION; PASSIVE TRANSPORT; PATHOGENESIS; PEMPHIGUS; REVIEW;

ANIMALS; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; IMMUNIZATION, PASSIVE; SKIN DISEASES, VESICULOBULLOUS;

EID: 72549096651     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2009.00948.x     Document Type: Review

References (72)

1. Sitaru C, Goebeler M, Zillikens D. Bullous autoimmune dermatoses (I): pathogenesis and diagnosis. J Dtsch Dermatol Ges 2004, 2:123-128.
2. Zillikens D, Burgdorf W H C, Plewig G, Wolff H H, Landthaler M. Autoimmune bullous skin diseases. Braun-Falco's Dermatology 2009, 641-670. In, eds, 3rd edn, Heidelberg, Springer
3. Stanley J R, Amagai M. Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. N Engl J Med 2006, 355:1800-1810.
4. Olasz E B, Yancey K B. Bullous pemphigoid and related subepidermal autoimmune blistering diseases. Curr Dir Autoimmun 2008, 10:141-166.
5. Olivry T, Dunston S M, Walker R H, Alhaidari Z, Messinger L, Liu Z. Investigations on the nature and pathogenicity of circulating antikeratinocyte antibodies in dogs with pemphigus foliaceus. Vet Dermatol 2009, 20:42-50.
6. Rosenkrantz W S. Pemphigus: current therapy. Vet Dermatol 2004, 15:90-98.
7. Preziosi D E, Goldschmidt M H, Greek J S. Feline pemphigus foliaceus: a retrospective analysis of 57 cases. Vet Dermatol 2003, 14:313-321.
8. Olivry T, Mirsky M L, Singleton W. A spontaneously arising porcine model of bullous pemphigoid. Arch Dermatol Res 2000, 292:37-45.
9. Olivry T, Borrillo A K, Xu L. Equine bullous pemphigoid IgG autoantibodies target linear epitopes in the NC16A ectodomain of collagen XVII (BP180, BPAG2). Vet Immunol Immunopathol 2000, 73:45-52.
10. Gammon W R, Lewis D M, Carlo J R, Sams W M, Wheeler C E. Pemphigoid antibody mediated attachment of peripheral blood leukocytes at the dermal-epidermal junction of human skin. J Invest Dermatol 1980, 75:334-339.
11. Sams W M, Gleich G J. Failure to transfer bullous pemphigoid with serum from patients. Proc Soc Exp Biol Med 1971, 136:1027-1031.
12. Anhalt G J, Bahn C F, Labib R S, Voorhees J J, Sugar A, Diaz L A. Pathogenic effects of bullous pemphigoid autoantibodies on rabbit corneal epithelium. J Clin Invest 1981, 68:1097-1101.
13. Anhalt G J, Labib R S, Voorhees J J, Beals T F, Diaz L A. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 1982, 306:1189-1196.
14. Anhalt G J, Till G O, Diaz L A, Labib R S, Patel H P, Eaglstein N F. Defining the role of complement in experimental pemphigus vulgaris in mice. J Immunol 1986, 137:2835-2840.
15. Takahashi Y, Patel H P, Labib R S, Diaz L A, Anhalt G J. Experimentally induced pemphigus vulgaris in neonatal BALB/c mice: a time-course study of clinical, immunologic, ultrastructural, and cytochemical changes. J Invest Dermatol 1985, 84:41-46.
16. Li N, Zhao M, Hilario-Vargas J. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 2005, 115:3440-3450.
17. Amagai M, Nishikawa T, Nousari H C, Anhalt G J, Hashimoto T. Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice. J Clin Invest 1998, 102:775-782.
18. Roscoe J T, Diaz L, Sampaio S A. Brazilian pemphigus foliaceus autoantibodies are pathogenic to BALB/c mice by passive transfer. J Invest Dermatol 1985, 85:538-541.
19. Amagai M, Hashimoto T, Green K J, Shimizu N, Nishikawa T. Antigen-specific immunoadsorption of pathogenic autoantibodies in pemphigus foliaceus. J Invest Dermatol 1995, 104:895-901.
20. Amagai M, Karpati S, Prussick R, Klaus-Kovtun V, Stanley J R. Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. J Clin Invest 1992, 90:919-926.
21. Amagai M, Hashimoto T, Shimizu N, Nishikawa T. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest 1994, 94:59-67.
22. Kasperkiewicz M, Zillikens D. The pathophysiology of bullous pemphigoid. Clin Rev Allergy Immunol 2007, 33:67-77.
23. Di Z G, Marazza G, Borradori L. Bullous pemphigoid: physiopathology, clinical features and management. Adv Dermatol 2007, 23:257-288.
24. Liu Z, Diaz L A, Troy J L. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 1993, 92:2480-2488.
25. Liu Z, Giudice G J, Swartz S J. The role of complement in experimental bullous pemphigoid. J Clin Invest 1995, 95:1539-1544.
26. Chen R, Ning G, Zhao M L. Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. J Clin Invest 2001, 108:1151-1158.
27. Liu Z, Giudice G J, Zhou X. A major role for neutrophils in experimental bullous pemphigoid. J Clin Invest 1997, 100:1256-1263.
28. Zhao M, Trimbeger M E, Li N, Diaz L A, Shapiro S D, Liu Z. Role of FcRs in animal model of autoimmune bullous pemphigoid. J Immunol 2006, 177:3398-3405.
29. Chen R, Fairley J A, Zhao M L. Macrophages, but not T and B lymphocytes, are critical for subepidermal blister formation in experimental bullous pemphigoid: macrophage-mediated neutrophil infiltration depends on mast cell activation. J Immunol 2002, 169:3987-3992.
30. Schön M, Ludwig R J. Leukocyte trafficking to inflamed skin - molecular mechanisms and implications for therapeutic target molecules. Expert Opin Ther Targets 2005, 9:225-243.
31. Liu Z, Zhao M, Li N, Diaz L A, Mayadas T N. Differential roles for beta2 integrins in experimental autoimmune bullous pemphigoid. Blood 2006, 107:1063-1069.
32. Liu Z, Zhou X, Shapiro S D. The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell 2000, 102:647-655.
33. Stanley J R, Hawley-Nelson P, Yuspa S H, Shevach E M, Katz S I. Characterization of bullous pemphigoid antigen: a unique basement membrane protein of stratified squamous epithelia. Cell 1981, 24:897-903.
34. Kiss M, Husz S, Janossy T. Experimental bullous pemphigoid generated in mice with an antigenic epitope of the human hemidesmosomal protein BP230. J Autoimmun 2005, 24:1-10.
35. Yamamoto K, Inoue N, Masuda R. Cloning of hamster type XVII collagen cDNA, and pathogenesis of anti-type XVII collagen antibody and complement in hamster bullous pemphigoid. J Invest Dermatol 2002, 118:485-492.
36. Gammon W R, Briggaman R A. Absence of specific histologic changes in guinea pig skin treated with bullous pemphigoid antibodies. J Invest Dermatol 1988, 90:495-500.
37. Naito K, Morioka S, Ikeda S, Ogawa H. Experimental bullous pemphigoid in guinea pigs: the role of pemphigoid antibodies, complement, and migrating cells. J Invest Dermatol 1984, 82:227-230.
38. Lazarova Z, Hsu R, Yee C, Yancey K B. Human anti-laminin 5 autoantibodies induce subepidermal blisters in an experimental human skin graft model. J Invest Dermatol 2000, 114:178-184.
39. Lazarova Z, Yee C, Darling T, Briggaman R A, Yancey K B. Passive transfer of anti-laminin 5 antibodies induces subepidermal blisters in neonatal mice. J Clin Invest 1996, 98:1509-1518.
40. Lazarova Z, Hsu R, Briggaman R A, Yancey K B. Fab fragments directed against laminin 5 induce subepidermal blisters in neonatal mice. Clin Immunol 2000, 95:26-32.
41. Borradori L, Caldwell J B, Briggaman R A. Passive transfer of autoantibodies from a patient with mutilating epidermolysis bullosa acquisita induces specific alterations in the skin of neonatal mice. Arch Dermatol 1995, 131:590-595.
42. Sitaru C, Mihai S, Otto C. Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J Clin Invest 2005, 115:870-878.
43. Woodley D T, Chang C, Saadat P, Ram R, Liu Z, Chen M. Evidence that anti-type VII collagen antibodies are pathogenic and responsible for the clinical, histological, and immunological features of epidermolysis bullosa acquisita. J Invest Dermatol 2005, 124:958-964.
44. Mihai S, Chiriac M T, Takahashi K. The alternative pathway of complement activation is critical for blister induction in experimental epidermolysis bullosa acquisita. J Immunol 2007, 178:6514-6521.
45. Chiriac M T, Roesler J, Sindrilaru A, Scharffetter-Kochanek K, Zillikens D, Sitaru C. NADPH oxidase is required for neutrophil-dependent autoantibody-induced tissue damage. J Pathol 2007, 212:56-65.
46. Sesarman A, Sitaru A G, Olaru F, Zillikens D, Sitaru C. The neonatal Fc-receptor promotes tissue injury in experimental epidermolysis bullosa acquisita. J Mol Med 2008, 86:951-959.
47. Woodley D T, Ram R, Doostan A. Induction of epidermolysis bullosa acquisita in mice by passive transfer of autoantibodies from patients. J Invest Dermatol 2006, 126:1323-1330.
48. Anhalt G J, Diaz L A. Animal models for bullous pemphigoid. Clin Dermatol 1987, 5:117-125.
49. Krause P J, Kristie J, Wang W P. Pentoxifylline enhancement of defective neutrophil function and host defense in neonatal mice. Am J Pathol 1987, 129:217-222.
50. Liechty K W, Schibler K R, Ohls R K, Perkins S L, Christensen R D. The failure of newborn mice infected with Escherichia coli to accelerate neutrophil production correlates with their failure to increase transcripts for granulocyte colony-stimulating factor and interleukin-6. Biol Neonate 1993, 64:331-340.
51. Buschard K, Dabelsteen E, Bretlau P. A model for the study of autoimmune diseases applied to pemphigus: transplants of human oral mucosa to athymic nude mice binds pemphigus antibodies in vivo. J Invest Dermatol 1981, 76:171-173.
52. Zillikens D, Schmidt E, Reimer S. Antibodies to desmogleins 1 and 3, but not to BP180, induce blisters in human skin grafted onto SCID mice. J Pathol 2001, 193:117-124.
53. Fairley J A, Burnett C T, Fu C L, Larson D L, Fleming M G, Giudice G J. A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice. J Invest Dermatol 2007, 127:2605-2611.
54. Zone J J, Taylor T, Hull C, Schmidt L, Meyer L. IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice. J Invest Dermatol 2007, 127:1167-1174.
55. Nishie W, Sawamura D, Goto M. Humanization of autoantigen. Nat Med 2007, 13:378-383.
56. Amagai M, Tsunoda K, Suzuki H, Nishifuji K, Koyasu S, Nishikawa T. Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus. J Clin Invest 2000, 105:625-631.
57. Aoki-Ota M, Tsunoda K, Ota T. A mouse model of pemphigus vulgaris by adoptive transfer of naive splenocytes from desmoglein 3 knockout mice. Br J Dermatol 2004, 151:346-354.
58. Aoki-Ota M, Kinoshita M, Ota T. Tolerance induction by the blockade of CD40/CD154 interaction in pemphigus vulgaris mouse model. J Invest Dermatol 2006, 126:105-113.
59. Takahashi H, Kuwana M, Amagai M. A single helper T cell clone is sufficient to commit polyclonal naive B cells to produce pathogenic IgG in experimental pemphigus vulgaris. J Immunol 2009, 182:1740-1745.
60. Takae Y, Nishikawa T, Amagai M. Pemphigus mouse model as a tool to evaluate various immunosuppressive therapies. Exp Dermatol 2009, 18:252-260.
61. Ujiie H, Shibaki A, Nishie W. Development of an active disease model for bullous pemphigoid. J Invest Dermatol 2008, 128:S10.
62. Olasz E B, Roh J, Yee C L. Human bullous pemphigoid antigen 2 transgenic skin elicits specific IgG in wild-type mice. J Invest Dermatol 2007, 127:2807-2817.
63. Hall R P, Murray J C, McCord M M, Rico M J, Streilein R D. Rabbits immunized with a peptide encoded for by the 230-kD bullous pemphigoid antigen cDNA develop an enhanced inflammatory response to UVB irradiation: a potential animal model for bullous pemphigoid. J Invest Dermatol 1993, 101:9-14.
64. Marietta E, Black K, Camilleri M. A new model for dermatitis herpetiformis that uses HLA-DQ8 transgenic NOD mice. J Clin Invest 2004, 114:1090-1097.
65. Sitaru C, Chiriac M T, Mihai S. Induction of complement-fixing autoantibodies against type VII collagen results in subepidermal blistering in mice. J Immunol 2006, 177:3461-3468.
66. Ludwig R J, Ishii N, Kasperkiewicz M, Chiriac M T, Zillikens D. Intravenous immunoglobulin (IVIG) is effective in experimental epidermolysis bullosa acquisita. J Invest Dermatol 2008, 128:S24.
67. Sitaru C, Sesarman A, Zillikens D, Solbach W, Hultmann P, Sitaru G. T cells are required for initiation of autoimmunity in epidermolysis bullosa acquisita. J Invest Dermatol 2008, 128:S5.
68. Eming R, Feliciani C, Eubel V, Podstawa E, Sonderstrup G, Hertl M. Immunodominant CD4+ T cell epitopes of human desmoglein 3 initiate pathogenic antibody response in an HLA-class-transgenic mouse model of pemphigus vulgaris. J Invest Dermatol 2008, 128:S22.
69. Ohyama M, Amagai M, Tsunoda K. Immunologic and histopathologic characterization of an active disease mouse model for pemphigus vulgaris. J Invest Dermatol 2002, 118:199-204.
70. Kawasaki H, Tsunoda K, Hata T, Ishii K, Yamada T, Amagai M. Synergistic pathogenic effects of combined mouse monoclonal anti-desmoglein 3 IgG antibodies on pemphigus vulgaris blister formation. J Invest Dermatol 2006, 126:2621-2630.
71. Takahashi H, Amagai M, Nishikawa T, Fujii Y, Kawakami Y, Kuwana M. Novel system evaluating in vivo pathogenicity of desmoglein 3-reactive T cell clones using murine pemphigus vulgaris. J Immunol 2008, 181:1526-1535.
72. Zone J J, Egan C A, Taylor T B, Meyer L J. IgA autoimmune disorders: development of a passive transfer mouse model. J Investig Dermatol Symp Proc 2004, 9:47-51.